Intravitreal Injections of Voriconazole for Candida Endophthalmitis: A Case Series.
Ocul Immunol Inflamm
; 28(3): 471-478, 2020 Apr 02.
Article
em En
| MEDLINE
| ID: mdl-30810429
ABSTRACT
Purpose:
Candida endophthalmitis represents a therapeutic challenge, considering the inability of many antifungals to achieve adequate concentrations in the vitreous. Intravitreal injection (IVI) of antifungals (amphotericin b deoxycholate or voriconazole) is therefore recommended. Whereas amphotericin b IVI is well documented, clinical data on voriconazole IVI are limited.Methods:
This was a retrospective review IRB approved of patients receiving voriconazole IVI for Candida endophthalmitis. Complete ophthalmological examination was completed at baseline and during follow-up.Results:
Five patients were treated with a mean four injections [range 2-9] of voriconazole (100 µg/0.1 mL saline). Improvement of visual acuity and disappearance of signs of infection were obtained in all patients. Safety concern including photoreceptor toxicity was not attributed to voriconazole IVI.Conclusions:
Voriconazole IVI demonstrated to be safe and led to a favorable clinical outcome. Thus, voriconazole IVI must be performed if Candida endophthalmitis is suspected to increase the chance of clinical success.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Candida albicans
/
Infecções Oculares Fúngicas
/
Endoftalmite
/
Voriconazol
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article